Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, February 12, 2015
The purpose of the new agreement is to ensure both organizations a future stronger position within the market for industrial consultancy.
read more
Monday, September 25, 2017
Geisinger and Boehringer Ingelheim announced a collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes that have long-term impact.
read more
Wednesday, August 12, 2015
GE has reached an agreement to sell $8.5 billion of healthcare-related loans and its Healthcare Financial Services (HFS) U.S. lending business to Capital One for approximately $9 billion.
read more
Tuesday, January 07, 2014
GE (NYSE:GE) and Thermo Fisher Scientific (NYSE:TMO) announced today that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for ...
read more
Friday, September 13, 2019
GE Healthcare and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy.
read more
Friday, December 20, 2019
GE Healthcare Life Sciences and ASLS will enter into a strategic R&D and distribution partnership that sets out to personalize tissue regeneration.
read more
Wednesday, November 02, 2016
GE Healthcare’s Life Sciences business has announced a $7M expansion project at its single-use technology manufacturing facility in Westborough, MA, US. The expanded site will manufacture a range of single-use products, including cell growth bags, ...
read more
Thursday, November 17, 2022
GE Healthcare’s Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway.
read more
Monday, November 07, 2016
GE Healthcare’s Life Sciences business and Valneva SE, a fully integrated vaccine biotech company, are sharing the results of a successful collaboration to optimize virus productivity in Valneva’s EB66® cell-line, a proprietary technology for the ...
read more
Thursday, October 17, 2024
GE HealthCare announced a collaboration with University Medicine Essen (UME) in the establishment of a new Theranostics Center of Excellence. The Center will be outfitted with the latest technologies and solutions to support the clinical practice and...
read more
GBG and its CRO arm Genesis Drug Discovery & Development has acquired the Cincinnati-based CRO STATKING Clinical Services.
read more
Genesis Drug Discovery & Development (GD3) has expanded its drug development services through the acquisition of a majority interest in NexusPharma.
read more
Wednesday, January 10, 2024
Formerly known as Goodwin Biotechnology, GBI BioManufacturing has proudly announced the execution of its second Master Supply Agreement (MSA) to bring a radioimmunoconjugate product to the commercial market.
read more
Wednesday, September 10, 2025
GBI Biomanufacturing (GBI) announced a partnership with NanoRetinal, Inc. to develop and manufacture NAR-001, NanoRetinal's proprietary nanoparticle technology designed to restore and/or preserve vision in patients with Inherited Retinal Diseases (...
read more
Thursday, November 21, 2024
GBI Biomanufacturing (GBI) announced the expansion of its Drug Product (DP) services, to include automated sterile fill and finish capabilities. GBI has the ability to support clients from clinical trials to commercial launch, for both Drug Substance...
read more